Tau kinetics in Alzheimer's disease

被引:11
|
作者
Hier, Daniel B. [1 ,2 ]
Azizi, Sima [1 ]
Thimgan, Matthew S. [3 ]
Wunsch II, Donald C. C. [1 ,4 ]
机构
[1] Missouri Univ Sci & Technol, Dept Elect & Comp Engn, Appl Computat Intelligence Lab, Rolla, MO 65409 USA
[2] Univ Illinois, Dept Neurol & Rehabil, Chicago, IL 60607 USA
[3] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO USA
[4] Natl Sci Fdn, ECCS Div, Alexandria, VA USA
来源
FRONTIERS IN AGING NEUROSCIENCE | 2022年 / 14卷
基金
美国国家科学基金会;
关键词
tau; Alzheimer's disease; CSF levels; plasma levels; steady state kinetics; halflife; turnover; clearance; FIBRILLARY ACIDIC PROTEIN; BRAIN INTERSTITIAL FLUID; NORMAL ORGAN WEIGHTS; II-THE-BRAIN; LONGITUDINAL STABILITY; MOUSE MODEL; PLASMA TAU; SECRETION; TURNOVER; SERUM;
D O I
10.3389/fnagi.2022.1055170
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The cytoskeletal protein tau is implicated in the pathogenesis of Alzheimer's disease which is characterized by intra-neuronal neurofibrillary tangles containing abnormally phosphorylated insoluble tau. Levels of soluble tau are elevated in the brain, the CSF, and the plasma of patients with Alzheimer's disease. To better understand the causes of these elevated levels of tau, we propose a three-compartment kinetic model (brain, CSF, and plasma). The model assumes that the synthesis of tau follows zero-order kinetics (uncorrelated with compartmental tau levels) and that the release, absorption, and clearance of tau is governed by first-order kinetics (linearly related to compartmental tau levels). Tau that is synthesized in the brain compartment can be released into the interstitial fluid, catabolized, or retained in neurofibrillary tangles. Tau released into the interstitial fluid can mix with the CSF and eventually drain to the plasma compartment. However, losses of tau in the drainage pathways may be significant. The kinetic model estimates half-life of tau in each compartment (552 h in the brain, 9.9 h in the CSF, and 10 h in the plasma). The kinetic model predicts that an increase in the neuronal tau synthesis rate or a decrease in tau catabolism rate best accounts for observed increases in tau levels in the brain, CSF, and plasma found in Alzheimer's disease. Furthermore, the model predicts that increases in brain half-life of tau in Alzheimer's disease should be attributed to decreased tau catabolism and not to increased tau synthesis. Most clearance of tau in the neuron occurs through catabolism rather than release to the CSF compartment. Additional experimental data would make ascertainment of the model parameters more precise.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] In vivo tau staging in Alzheimer's disease
    Therriault, Joseph
    Gauthier, Serge
    Rosa-Neto, Pedro
    AGING-US, 2022, 14 (17): : 6842 - 6843
  • [22] Plasma tau levels in Alzheimer's disease
    Henrik Zetterberg
    David Wilson
    Ulf Andreasson
    Lennart Minthon
    Kaj Blennow
    Jeffrey Randall
    Oskar Hansson
    Alzheimer's Research & Therapy, 5
  • [23] Alzheimer's disease:: Aβ, tau and synaptic dysfunction
    LaFerla, FM
    Oddo, S
    TRENDS IN MOLECULAR MEDICINE, 2005, 11 (04) : 170 - 176
  • [24] A Novel Perspective on Tau in Alzheimer's Disease
    Bonda, D. J.
    Castellani, R. J.
    Zhu, X.
    Nunomura, A.
    Lee, H. -g.
    Perry, G.
    Smith, M. A.
    CURRENT ALZHEIMER RESEARCH, 2011, 8 (06) : 639 - 642
  • [25] Plasma tau levels in Alzheimer's disease
    Zetterberg, Henrik
    Wilson, David
    Andreasson, Ulf
    Minthon, Lennart
    Blennow, Kaj
    Randall, Jeffrey
    Hansson, Oskar
    ALZHEIMERS RESEARCH & THERAPY, 2013, 5 (02):
  • [26] Targeting Tau Protein in Alzheimer’s Disease
    Cheng-Xin Gong
    Inge Grundke-Iqbal
    Khalid Iqbal
    Drugs & Aging, 2010, 27 : 351 - 365
  • [27] Tau as a Therapeutic Target for Alzheimer's Disease
    Boutajangout, A.
    Sigurdsson, E. M.
    Krishnamurthy, P. K.
    CURRENT ALZHEIMER RESEARCH, 2011, 8 (06) : 666 - 677
  • [28] Tau polymorphisms are not associated with Alzheimer's disease
    Kwon, JM
    Nowotny, P
    Shah, PK
    Chakraverty, S
    Norton, J
    Morris, JC
    Goate, AM
    NEUROSCIENCE LETTERS, 2000, 284 (1-2) : 77 - 80
  • [29] Tau PET Imaging in Alzheimer's Disease
    Okamura, Nobuyuki
    Harada, Ryuichi
    Furumoto, Shozo
    Arai, Hiroyuki
    Yanai, Kazuhiko
    Kudo, Yukitsuka
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2014, 14 (11)
  • [30] In vivo tau imaging in Alzheimer's disease
    Villemagne, Victor
    Furumoto, Shozo
    Fodero-Tavoletti, Michelle
    Mulligan, Rachel
    Hodges, John
    Kudo, Yukitsuka
    Masters, Colin
    Yanai, Kazuhiko
    Rowe, Christopher
    Okamura, Nobuyuki
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53